Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BME
Upturn stock ratingUpturn stock rating

BlackRock Health Sciences Trust (BME)

Upturn stock ratingUpturn stock rating
$36.65
Last Close (24-hour delay)
Profit since last BUY-0.22%
upturn advisory
Consider higher Upturn Star rating
BUY since 6 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: BME (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 2.33%
Avg. Invested days 46
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 468.11M USD
Price to earnings Ratio 22.22
1Y Target Price -
Price to earnings Ratio 22.22
1Y Target Price -
Volume (30-day avg) -
Beta 0.63
52 Weeks Range 33.44 - 39.99
Updated Date 06/29/2025
52 Weeks Range 33.44 - 39.99
Updated Date 06/29/2025
Dividends yield (FY) 8.68%
Basic EPS (TTM) 1.63

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 309.96%
Operating Margin (TTM) 1.96%

Management Effectiveness

Return on Assets (TTM) 0.1%
Return on Equity (TTM) 4.14%

Valuation

Trailing PE 22.22
Forward PE -
Enterprise Value 480385856
Price to Sales(TTM) 61.86
Enterprise Value 480385856
Price to Sales(TTM) 61.86
Enterprise Value to Revenue 19.45
Enterprise Value to EBITDA -
Shares Outstanding 12924100
Shares Floating -
Shares Outstanding 12924100
Shares Floating -
Percent Insiders -
Percent Institutions 21.79

ai summary icon Upturn AI SWOT

BlackRock Health Sciences Trust

stock logo

Company Overview

overview logo History and Background

BlackRock Health Sciences Trust (BME) is a closed-end equity fund. It was incepted on October 29, 2005. It invests in companies engaged in the health sciences and related industries.

business area logo Core Business Areas

  • Equity Investments: The fund primarily invests in equity securities of companies in the health sciences and related industries, including pharmaceutical, biotechnology, medical technology, and healthcare services companies.

leadership logo Leadership and Structure

BME is managed by BlackRock Advisors, LLC. BlackRock is a global investment management firm, and its leadership team consists of seasoned professionals with expertise in investment management, portfolio construction, and risk management. The fund's portfolio managers are responsible for making investment decisions based on their analysis of market trends and company fundamentals.

Top Products and Market Share

overview logo Key Offerings

  • Closed-End Fund: BME is a closed-end fund, meaning it issues a fixed number of shares that trade on the stock exchange. Its focus is solely on investment within the health science industry. Competitors include Tekla Healthcare Opportunities Fund (THQ), Columbia Seligman Premium Tech Growth Fund (STK) and Eaton Vance Healthcare Fund (ETV).

Market Dynamics

industry overview logo Industry Overview

The health sciences industry is characterized by innovation, regulation, and demographic shifts. It's a sector with high growth potential due to aging populations and advancements in medical technology.

Positioning

BME is positioned as an investment vehicle for investors seeking exposure to the growth potential of the health sciences industry through a diversified portfolio of companies.

Total Addressable Market (TAM)

The global healthcare market is estimated to be in the trillions of dollars. BME is positioned to capture a portion of this market by investing in companies across various sub-sectors within the health sciences industry.

Upturn SWOT Analysis

Strengths

  • Experienced management team
  • Diversified portfolio within the health sciences sector
  • Access to BlackRock's global research resources

Weaknesses

  • Closed-end fund structure can lead to trading at a discount to NAV
  • Subject to market volatility
  • Management fees can impact returns

Opportunities

  • Growth in emerging markets healthcare
  • Advancements in medical technology and biotechnology
  • Increasing demand for healthcare services due to aging populations

Threats

  • Regulatory changes in the healthcare industry
  • Economic downturns affecting healthcare spending
  • Competition from other investment vehicles

Competitors and Market Share

competitor logo Key Competitors

  • THQ
  • STK
  • ETV

Competitive Landscape

BME's advantages include BlackRock's brand and research capabilities. Disadvantages could include higher management fees or underperformance compared to peers.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends would be evaluated based on the fund's performance over the past several years.

Future Projections: Future growth projections would rely on analyst estimates and market forecasts for the health sciences industry.

Recent Initiatives: Recent strategic initiatives would include any changes in the fund's investment strategy or portfolio composition.

Summary

BlackRock Health Sciences Trust offers investors access to the health sciences sector through a managed portfolio. The fund's performance is influenced by industry dynamics and market conditions. BME benefits from BlackRock's expertise but faces competition and market risks. Monitoring its NAV, distributions, and competitive positioning is crucial. While it has strengths in management and access to resources, it is crucial to be mindful of the volatility within the stock market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • BlackRock official website
  • Financial data providers (e.g., Bloomberg, Reuters)
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results. Market conditions and fund performance can change. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About BlackRock Health Sciences Trust

Exchange NYSE
Headquaters New York, NY, United States
IPO Launch date 2005-03-29
CEO -
Sector Financial Services
Industry Asset Management
Full time employees -
Full time employees -

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.